

REMARKS

Applicants elect with traverse Group I (claims 1-42, 45 and 47-69) for examination on the merits. Traversal is on the grounds that it would not constitute an undue burden on the Examiner to search and examine both groups of claims in one application.

With respect to the requirement to elect a species for examination, Applicants elect an ADP-ribosylating exotoxin and, further elect *E. coli* heat-labile enterotoxin (LT). Claims 1-29, 41-42, 53-54 and 57-69 read on the elected species.

Applicants urge that the claims are in condition for allowance and earnestly solicit an early Notice to that effect. The Examiner is invited to contact the undersigned if any further information is needed.

Respectfully submitted,

Intellectual Property Group of
PILLSBURY WINTHROP, L.L.P.

By Paul N. Kokulis 43180
for Paul N. Kokulis
Reg. No. 16,773

1100 New York Avenue, N.W.
Ninth Floor – East Tower
Washington, D.C. 20005-3918
Telephone: (202) 861-3000

APPENDIX
MARKED-UP VERSION TO SHOW CHANGES

IN THE CLAIMS:

The claims are amended as follows.

54. (Amended) A method of claim 1, wherein the induced immune response recognizes an ADP-ribosylating exotoxin selected from the group consisting of E. coli heat-labile enterotoxin (LT), cholera toxin (CT), diphtheria toxin (DT), pertussis toxin (PT), and tetanus toxin (TT).